The cellular state space of AML unveils novel NPM1 subtypes with distinct clinical outcomes and immune evasion properties
Acute myeloid leukemia (AML) is a genetically and cellularly heterogeneous disease. We characterized 120 AMLs using bulk genomic and transcriptomic analyses (WES, MP-WGS, RNA-seq), and single-cell RNA sequencing (scRNA-seq). Our results reveal an extensive cellular heterogeneity that distorts the bulk transcriptomic profiles. Notably, NPM1 mutated AML could be stratified into two novel, clinically relevant classes (NPM1class I and NPM1class II).
- Type: Transcriptome Analysis
- Archiver: Federated European Genome-Phenome Archive (FEGA Sweden)
Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data
| Dataset ID | Description | Technology | Samples |
|---|---|---|---|
| EGAD50000001574 | NextSeq 500 | 98 | |
| EGAD50000001575 | NextSeq 500 | 232 | |
| EGAD50000001576 | NextSeq 500 | 120 | |
| EGAD50000001577 | unspecified | 72 |
| Publications | Citations |
|---|---|
|
Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia.
Nat Cancer 6: 2025 1821-1838 |
0 |
|
The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes.
Nat Commun 16: 2025 10592 |
1 |
